Kavar Capital Partners Group’s GSK GSK Stock Holding History

Kavar Capital Partners Group’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-4,597	Closed	-$254K	–	217
2026 Q1	$254K	Hold	4,597	–	–	0.03%	185
2025 Q4	$225K	Sell	4,597 -288	-6%	-$13.4K	0.03%	171
2025 Q3	$211K	Buy	+4,885	New	+$191K	0.03%	177
2025 Q2	–	Sell	-28,335	Closed	-$1.1M	–	196
2025 Q1	$1.1M	Sell	28,335 -395	-1%	-$14.5K	0.18%	91
2024 Q4	$972K	Sell	28,730 -3,742	-12%	-$135K	0.16%	92
2024 Q3	$1.33M	Sell	32,472 -460	-1%	-$18.8K	0.21%	89
2024 Q2	$1.27M	Sell	32,932 -662	-2%	-$27.8K	0.23%	82
2024 Q1	$1.44M	Sell	33,594 -6,280	-16%	-$259K	0.27%	78
2023 Q4	$1.48M	Sell	39,874 -10,601	-21%	-$381K	0.17%	87
2023 Q3	$1.83M	Buy	50,475 +1,107	+2%	+$39.3K	0.4%	66
2023 Q2	$1.76M	Sell	49,368 -3,871	-7%	-$139K	0.37%	68
2023 Q1	$1.89M	Sell	53,239 -1,586	-3%	-$55.5K	0.41%	65
2022 Q4	$1.93M	Sell	54,825 -5,685	-9%	-$189K	0.44%	63
2022 Q3	$1.78M	Buy	+60,510	New	+$2.29M	0.45%	63
2022 Q2	–	Sell	-51,390	Closed	-$2.8M	–	172
2022 Q1	$2.8M	Buy	51,390 +960	+2%	+$52.1K	0.6%	47
2021 Q4	$2.78M	Buy	50,430 +548	+1%	+$28.5K	0.58%	53
2021 Q3	$2.38M	Buy	49,882 +2,132	+4%	+$107K	0.54%	55
2021 Q2	$2.38M	Sell	47,750 -1,040	-2%	-$50K	0.57%	53
2021 Q1	$2.18M	Buy	48,790 +236	+0.5%	+$10.7K	0.59%	53
2020 Q4	$2.23M	Buy	48,554 +2,110	+5%	+$96.9K	0.64%	48
2020 Q3	$2.19M	Buy	46,444 +3,860	+9%	+$193K	0.74%	45
2020 Q2	$2.17M	Buy	42,584 +2,532	+6%	+$130K	0.83%	43
2020 Q1	$1.9M	Buy	40,052 +388	+1%	+$20.7K	0.91%	37
2019 Q4	$2.33M	Sell	39,664 -200	-0.5%	-$11.1K	0.86%	45
2019 Q3	$2.13M	Sell	39,864 -200	-0.5%	-$10.3K	0.83%	47
2019 Q2	$2M	Buy	40,064 +2,108	+6%	+$106K	0.79%	48
2019 Q1	$1.98M	Buy	37,956 +376	+1%	+$18.8K	0.88%	45
2018 Q4	$1.79M	Sell	37,580 -536	-1%	-$26.4K	0.97%	42
2018 Q3	$1.91M	Buy	38,116 +296	+0.8%	+$15K	0.95%	48
2018 Q2	$1.91M	Buy	37,820 +180	+0.5%	+$9.07K	0.96%	43
2018 Q1	$1.84M	Buy	37,640 +29,000	+336%	+$1.35M	0.96%	44
2017 Q4	$383K	Sell	8,640 -27,216	-76%	-$1.26M	0.2%	80
2017 Q3	$1.82M	Sell	35,856 -240	-0.7%	-$12.2K	1%	45
2017 Q2	$1.95M	Sell	36,096 -980	-3%	-$52.2K	1.06%	44
2017 Q1	$1.95M	Buy	37,076 +3,220	+10%	+$163K	1.09%	41
2016 Q4	$1.63M	Buy	33,856 +1,700	+5%	+$84K	1.03%	48
2016 Q3	$1.73M	Buy	32,156 +2,036	+7%	+$112K	1.12%	43
2016 Q2	$1.63M	Buy	30,120 +40	+0.1%	+$2.11K	1.05%	45
2016 Q1	$1.52M	Buy	30,080 +2,573	+9%	+$128K	1.01%	50
2015 Q4	$1.39M	Sell	27,507 -5,440	-17%	-$277K	0.89%	50
2015 Q3	$1.58M	Buy	32,947 +3,280	+11%	+$171K	1.12%	39
2015 Q2	$1.54M	Buy	29,667 +1,484	+5%	+$83.6K	1.05%	37
2015 Q1	$1.63M	Buy	28,183 +1,493	+6%	+$85.6K	1.38%	29
2014 Q4	$1.43M	Buy	26,690 +200	+0.8%	+$11.2K	1.12%	31
2014 Q3	$1.52M	Buy	26,490 +12,720	+92%	+$780K	1.3%	19
2014 Q2	$920K	Buy	13,770 +3,760	+38%	+$255K	0.78%	59
2014 Q1	$668K	Buy	10,010 +1,480	+17%	+$100K	0.55%	78
2013 Q4	$569K	Buy	+8,530	New	+$553K	0.51%	76

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Kavar Capital Partners Group's GSK Position: Q2 2026 in Review

Kavar Capital Partners Group sold out of GSK (GSK) in Q2 2026, closing a stake of 4,597 shares — an estimated $254K sold.

Kavar Capital Partners Group first reported a position in GSK in Q4 2013 and held it in 48 quarters. The position peaked at $2.8M in Q1 2022. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Kavar Capital Partners Group reported no remaining GSK position as of Q2 2026 after selling out during the quarter.
Kavar Capital Partners Group sold 4,597 GSK shares in Q2 2026, an estimated $254K.
Kavar Capital Partners Group first reported a position in GSK in Q4 2013 and held it in 48 quarters.
Kavar Capital Partners Group's GSK position peaked at $2.8M in Q1 2022.
1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Kavar Capital Partners Group's 13F filing for Q2 2026, filed 20 Jul 2026.